Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).
A. M. Gonzalez-Angulo
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
M. C. Green
No relevant relationships to disclose
J. L. Murray
No relevant relationships to disclose
S. L. Palla
No relevant relationships to disclose
K. H. Koenig
No relevant relationships to disclose
A. M. Brewster
No relevant relationships to disclose
V. Valero
No relevant relationships to disclose
N. K. Ibrahim
No relevant relationships to disclose
S. L. Moulder
No relevant relationships to disclose
J. K. Litton
Research Funding - Novartis
D. J. Crawford
No relevant relationships to disclose
P. R. Flores
No relevant relationships to disclose
M. J. Dryden
No relevant relationships to disclose
W. F. Symmans
No relevant relationships to disclose
S. H. Giordano
No relevant relationships to disclose
L. Pusztai
No relevant relationships to disclose
A. Buzdar
No relevant relationships to disclose
G. B. Mills
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
G. N. Hortobagyi
No relevant relationships to disclose
F. Meric-Bernstam
Research Funding - Novartis